Merck KGaA (MRK) Earnings Call Transcript & Summary
November 10, 2022
Earnings Call Speaker Segments
Operator
operatorGood day, everyone, and thank you for joining us for the Merck Investor and Analyst Conference Call covering the third quarter of 2022. Just a quick note that everyone on the line will be in listen-only mode for this session. At this point I'll turn things over to Constantin Fest, our Head of Investor Relations, and he'll guide you through the conference. Constantin, please go ahead.
Constantin Fest
executiveThank you so much, Xanga. Ladies and gentlemen, welcome warmly to this call covering Merck's Q3 2022 results. I'm Constantine Fest, Head of Investor Relations. It's a pleasure to have with us today Belen Garijo, our Group CEO, along with Marcus Kuhnert, Group CFO. For the Q&A portion of this call, Peter Guenter, CEO of Healthcare, will also join us, as will Matthias Heinzel, CEO of Life Science, and Kai Beckmann, CEO of Electronics. Over the next few minutes, we want to walk you through the presentation's key slides. And immediately afterward, we'll be glad to take your questions. With that said, I'd now like to pass things to Belen to get the presentation started. Belen, over to you.
Belén Garijo
executiveThanks, Constantin. Good afternoon, everyone, and welcome to our Q3 earnings call. I'll begin with the highlights found on slide number five of the presentation. First and foremost, we delivered a strong third quarter mainly driven by life science and healthcare. Group sales rose 7.1% organically, and EBITDA pre increased by 7.5%, so faster than sales. Along with significant currency tailwinds and a small portfolio effects related to accelerate report sales and EBITDA pre amounted to €5.8 billion and €1.8 billion respectively. EBS pre of 2.68 was up 20% year-on-year. We delivered this growth despite a very challenging external operating environment as you will know. Global economic activities experiencing a broad base of slowdown, inflation continues to rise to rise to levels not seen in decades and the risks to the global economy outlook remain very significant. Just think of the tightening financial conditions in most regions, the ongoing pandemic and of course, multiple geopolitical tensions, starting by the Russia's war in Ukraine. However, as recently discussed with all of you, as our region Capital Markets Day, our company is highly resilient and solidly positioned to navigate these uncertain times. Based on our multi industry setup, we are generally less exposed to macro economic downturns.
Belén Garijo
executiveOn top of that, our attention is on markets where the underlying upward momentum is robust. Our financial foundation is exceptionally solid. We're carrying out our growth strategy, and we keep strengthening the resilience of our supply chain so we can handle the challenges even better. Because of this, we're not just positioned to get through the current turbulent period — we think we can come out of this global crisis with extra competitive advantages in certain areas, like semi materials. Q3 is just one more example: despite major external headwinds in individual areas, specifically display solutions, we delivered strong growth. That came thanks to the excellent performance of our Big 3, our major growth engine. We also made further progress on delivering our strategic agendas, with highlights including our €130 million investment in Molsheim to strengthen our single use franchise in Process Solutions, and the acquisition of the chemical business of Mecaro to keep driving innovation in semis, plus encouraging data updates for our healthcare latest stage blockbuster potential candidates, Evobrutinib and Xevinapant. Above all, today we confirmed our absolute guidance ranges for 2022 for both sales and EBITDA pre, as well as for EPS pre. With the deal coming to an end, we now forecast group net sales in the range of €22 billion to €22.9 billion, EBITDA pre of €6.8 billion to €7.2 billion, and EPS pre of €9.9 to €10.7 years.
Belén Garijo
executiveAdditional specifics regarding what we're assuming will come afterward. If you turn to slide 6, I can give you a little more insight into how each business sector performed. As you can see, every one of the three sectors played a part in the robust organic sales increase we posted in Q3. The Big 3 — process solutions and life science services, semiconductors, and the new healthcare launches — remain fully on track and made up roughly 80% of organic growth in Q3. Life science delivered another solid quarter, with organic sales rising 9%. Healthcare likewise did well, posting 9% organic growth, while electronics came in slightly higher. Foreign exchange gave a meaningful boost pretty much everywhere, contributing 9% to both group sales and EBITDA pre. On top of that, there was a modest portfolio impact arising, as I noted earlier, from the Exelead acquisition. Inside Life Science, the gain came from the core business continuing to perform strongly, expanding 16% organically, which more than compensated for the expected drop in COVID-related sales versus those comparables. Process Solutions was again the biggest driver, with 11% organic growth and a outstanding 31% organic growth once COVID sales decline is excluded. SLS, Science and Lab Solutions posted robust organic growth of 8%, whereas Life Science Services was subdued at 3% because of some fluctuation in the CDMO business, which, as you might remember, generates substantial growth in Q2, and Matthias can say more on that during Q&A should it be needed.
Belén Garijo
executiveThe healthcare segment's robust sales gain came from 26% organic growth in recent launches plus solid mid single digit expansion in the established portfolio. On that front, we benefited from easier comparables and channel dynamics—something we can also cover in the Q&A—along with catch-up effects in emerging markets. In electronics, our semiconductor solutions business, which now accounts for 70% of electronics sector sales, keeps shining with 15% organic growth against tougher comparables. Surface Solutions rose 4%, with strong semis performance offsetting a 32% drop in display solutions. Turning to earnings, Group EBITDA pre reached €1.81 billion in Q3, producing a strong 31.2% margin, level with the prior year despite significantly higher input costs. Let me wrap up this section with a few comments on regional sales. In Q3, every region added to the positive organic development, leading in absolute terms with 10% growth in Europe and 7% in North America. Low single digit growth in Asia Pacific stemmed mainly from a significant decline in liquid crystals, while other businesses performed strongly, including catch-up effects in China after the Q2 lockdowns. Our smallest regions, Latin America and Middle East and Africa, each delivered strong double digit growth.
Belén Garijo
executiveSo all in all, Q3 once more shows what makes our globally diversified business so advantageous, strong, and resilient. As we discussed with you at the recent Capital Markets Day, we'll keep driving regionalization of our manufacturing footprint and further strengthening our supply chains in order to serve regional demand, improve how close we are to customers, and lower our network risk. With that, I'll turn things over to Marcus for more detail on our Q3 financials.
Marcus Kuhnert
executiveThanks, Belen, and hello from me as well. Now let's move to slide nine, which gives an overview of the key figures for the quarter. All in all, Q3 was strong, with sales and earnings both growing by double digits. Organic growth came in at a high single digit rate, and that was supplemented by a substantial tailwind from foreign exchange, plus, as Belen noted, a modest portfolio contribution from Exelead. To start with, net sales rose 16.8% to €5,806 million. BITDA pre climbed 16.7% to €1.81 billion, while EPS pre advanced nearly 20% to €2.68. Operating cash flow reached €1.55 billion, a rise of 5% year-on-year, as favorable effects from higher earnings were partially offset by greater tax cash outflows and also by increased net working capital. Net financial debt went up by close to €500 million relative to the end of December, primarily because of the temporary investment of surplus cash. Put differently, the purchase price for the Exelead acquisition, along with higher CapEx and the dividends, has already been more than covered by our solid free cash flow calculation for the year to date. As a result, the ratio of net debt to EBITDA pre stayed stable at 1.4 times. Please also keep in mind that headcount is up 5% year to date as we support our growth ambitions.
Marcus Kuhnert
executiveAllow me to give a quick rundown of the financial results we reported. I'm on slide number 10. In absolute terms, EBIT rose by €187 million during the third quarter. That figure sits €71 million below EBITDA pre gross, largely because adjustments were higher and D&A was higher. The financial result saw a €7 million improvement, since a better interest result was partly offset by higher LTIP provisions. Our effective tax rate landed at 22%, placing it at the lower end of the range we guided. Consequently, net income and reported earnings per share each climbed by 21%. You may have noticed that we raised our guidance for the interest result in 2022. Keep in mind this includes roughly €40 million of income tied to the recent partial buyback of our hybrid bond as well as new tax rules in Germany from earlier this year. That will go away next year. Meanwhile, we are trending toward the lower end of our effective tax rate guidance for 2022. And we expect to drop below the corridor — the current corridor — as we move into 2023. As always, we'll give concrete guidance on the interest result and effective tax rate for 2023 alongside our Q4 results in March.
Marcus Kuhnert
executiveOkay, just a quick heads-up so it helps with your modeling — overall, we see these effects as roughly neutral for EPS before next year. Now let's turn to revenue by business sector, and I'll begin with Life Sciences on slide number 11. As Belen already mentioned, Life Science delivered another strong quarter, with sales up 8.7% organically. The core business grew an excellent 16% again, on par with Q2, and that more than offset a somewhat more pronounced COVID impact of minus 7%. Total COVID-related sales fell by roughly 30% versus the peak in Q3 of last year, and sequentially they were about stable, reflecting auto phasing and fully in line with what we expected. On the portfolio side, process solutions stayed the key driver, with organic sales growth of 11%. Within that, the core business rose by a record 31%, while the drag from declining COVID sales was minus 20%. Lead times improved further, and key portfolios such as single use and filtration benefited from the ongoing ramp-up of new capacities. Order intake kept declining as expected, and book-to-bill came in slightly below one. That means we were able to bring down some of our still significant backlog, which is good news.
Marcus Kuhnert
executiveNow looking at Life Science Services. This quarter's growth was subdued, coming in at 3% on an organic basis. That figure reflects a 17% decline in the core business, which was more than compensated for by a favorable contribution from COVID-related sales of 20%, stemming from auto phasing. Our more mature contract testing business kept delivering double-digit growth, whereas the CDMO business felt the effects of unfavorable batch phasing and attrition in the clinical pipelines of our customers. Science and Lab Solutions delivered a robust quarter, with sales rising 7.9% organically, helped by favorable pricing and growth across nearly every business line. Lab Water and Biomonitoring once again reached double-digit territory, the core business climbed 9% organically, and the COVID effect was modest, at minus 1%. On a geographic basis, we achieved double-digit organic growth in nearly every region. Looking at customers, sales to pharma and biotech, our biggest customer segment, rose organically in the high single digits. Diagnostics and academia came in at mid single digits, while industrial and testing surpassed even 10%. On the earnings side, EBITDA pre reached €976 million, up 10.8% organically, with a robust margin of 36.4%. That was modestly lower year-on-year, by 20 basis points, largely because of currencies.
Marcus Kuhnert
executiveFavorable product mix in the core business, along with strong pricing and operating leverage, was largely offset at the margin level by a smaller share of COVID business, continued strategic investments and input cost inflation. Now turning to healthcare on slide 12. Here quarterly sales pass the €2 billion mark for the very first time. Naturally, FX tailwinds provided support here. Even so, organic growth was very strong as well — in fact, slightly higher, at 8.7%, on the back of 26% growth from recently launched products and a solid 5% increase in the established portfolio. By franchise, oncology once again led growth, with sales rising 25% organically. This reflected the continued strong ramp-up of Bavencio, which grew 51% organically year-on-year and 14% quarter-to-quarter. I'd also like to point out Erbitux's strong showing at 14%, including double-digit growth in China following Erbitux head and neck inclusion in the NRDL earlier this year. The N&I franchise rose 2.3% organically, as 10% growth from Mavenclad more than offset a decline of just minus 4% for Rebif. Please note, though, that Rebif benefited from one of channel dynamics and lower comps during the third quarter. Our fertility franchise returned to growth, with sales up 2.6%, mainly thanks to a fading impact from the lockdowns in China.
Marcus Kuhnert
executiveCM&E sales rose 6% organically, driven by solid results from Euthyrox and Saizen across regions, while Glucophage went back to growth. On the pipeline side, recent updates to late-stage potential blockbuster candidates are among the highlights. At ECTRIMS, we presented new Evobrutinib data showing sustained clinical benefit for relapsing multiple sclerosis patients through three and a half years of treatment — the first BTKI to achieve that. At ESMO, we presented five-year Xevinapant data showing survival rates nearly doubled in patients with unresected locally advanced squamous cell carcinoma of the head and neck when it was added to standard of care. Also, the second Phase 3 trial of Xevinapant — Xray vision in SCCHN — has begun in resected cisplatin-ineligible patients and is recruiting now. We'll share more on CDMO and other r assets in development during the R&D update call on the 21st of November. Turning to earnings, EBITDA pre came to €711 million, producing a strong 34% margin helped by currency. Organic EBITDA pre growth of 11% outpaced sales growth amid controlled cost development, including R&D phasing and the one-off channel dynamics I mentioned earlier. As for income from active portfolio management, we booked a low single digit euro million amount in Q3 and are therefore now near €40 million for the first nine months of the year.
Marcus Kuhnert
executiveAs a result, we have increased our guidance for the entire year on income from active portfolio management, moving it from a low to mid double digit figure to a mid double digit million euro amount. That means we might witness an additional modest contribution during the first quarter. When we look at 2023 and consider the factors pushing and pulling on the margin, here is what I would like to say. First, wage inflation might grow more pronounced, and we stand ready to put investment into pre commercial activities for the Evobrutinib launch. Second, we ought to get some support for the margin from a larger proportion of new products along with cost discipline, R&D included. The net effect is still not certain, and we intend to provide you with more color when we report Q4 results in March. Moving to electronics on slide number 13. Electronics surpassed the €1 billion mark in quarterly sales for the first time, helped by FX, whereas organically sales rose just slightly, by 0.4% in the third quarter. Semiconductor solutions, our key growth engine within electronics, keeps performing strongly, with organic growth of 15% against rising comps. Fossil fuel for high teens growth and semi materials aided by volume and pricing. And with growth across every material category, thin film patterning and spec gases included.
Marcus Kuhnert
executiveKey underlying factors worth highlighting are new notes, fabs, and leading edge. Beyond that, we recorded additional expansion in DS&S, driven by robust equipment sales. That growth fell short of prior quarters because the big projects annualized, something we first called out in Q3 2021. Meanwhile, we have already booked a new large turnkey project of comparable size. Sales in display solutions declined 32% organically, driven chiefly by a major slowdown in demand across the display value chain, particularly for liquid crystals, and therefore substantially reduced plant utilization at key customers. Surface Solution delivered healthy organic growth of 4%, since weakness in industrials was more than outweighed by robust coatings and cosmetics sales. EBITDA pre came in at €302 million, a solid 29.1% margin, though that was down 260 basis points year on year, even with foreign exchange support, given the extremely difficult macroeconomic environment. On an organic basis, EBITDA pre fell minus 14.8%, largely because of display solutions, amid inflationary pressure and capacity ramp up for future growth. Importantly, please note that semi margins remain intact. Before I hand back to Belen for the outlook, let me briefly comment on our balance sheet and cash flow statement.
Marcus Kuhnert
executiveSlide 14 shows our balance sheet grew €5.5 billion versus the close of December. Business growth and currency are the primary forces driving that. Looking at assets, cash and cash equivalents fell, mostly because excess cash was temporarily invested, and that will reverse by year-end. Receivables and inventories rose on stronger sales, inflationary effects, larger safety stocks and FX, while intangibles climbed on FX and the Exelead acquisition. On the liabilities side, financial debt edged up from issuing a new bond. Pension provisions declined mainly thanks to actuarial gains from rising interest rates, and equity rose on growth and profit after tax, actuarial gains and favorable FX effects. Consequently, the equity ratio strengthened again, moving from 47% at December's end to 56% at the close of September. Briefly on cash flows, slide 50, operating cash flow for Q3 reached €1.55 billion, a €85 million increase year-on-year. That mirrors higher earnings and robust cash conversion of 86%, along with greater working capital, notably larger inventories from inflationary effects and increased safety stocks.
Marcus Kuhnert
executiveInvesting activities cash out stayed about level, even though CapEx rose €89 million year-on-year to back our organic growth initiatives. Finally, the gap in financing cash flow comes down to larger net repayments of financial debt in the prior-year period. With that said, I'll return things to Belen for the outlook.
Belén Garijo
executiveThank you, Marcus. Let's turn to slide number 17, where we'll go through the full year guidance for the group. Let me start by restating something. Our Q3 results were very strong. Once again, we saw excellent resilience growth despite a challenging external operating environment. And as we look ahead, we believe these headwinds will persist for some time and could eventually become even stronger. Even so, we stay firmly committed to our mid-term ambition of 25x25 and fully confirm our absolute sales and earnings target corridors for 2022. In fact, we have become somewhat more precise, now guiding to group net sales in 2022 in a range of €22 billion to €22.9 billion, EBITDA pre in a range of €6.8 billion to €7.2 billion, and EPS pre in a range of €9.9 to €10.7. And this is based on organic sales growth of 6% to 8% and organic EBITDA pre growth of 5% to 9%. So, while we have tweaked slightly the appearance of the organic sales growth guidance, our organic EBITDA pre growth remains unchanged versus our communication in cost. Our currency assumptions also remain the same as before. And we expect tailwinds of 5% to 8% for sales and 6% to 8% for EBITDA pre.
Belén Garijo
executiveNow I'll walk you through a few more specifics about our guidance, broken out by business sector, on slide number 18. As you can see, we still anticipate that organic sales growth in 2022 will have support from all three business sectors. That said, organic, organic EBITDA pre growth is now expected to come primarily from Life Science and Healthcare. Where Electronics is concerned, we've grown more cautious regarding both organic sales and EBITDA pre development in 2022. The main reason is substantially weaker demand for liquid crystals materials, which ties to lower fab utilization at customer level. Our confidence stays very high in how strongly semiconductor solution will perform this year. I noted earlier that semi accounts for 70% of the revenues of electronics. Yet, as we told you at the capital market today, we foresee a possible market slowdown next year. Meanwhile, the meter outlook for semi is still highly compelling, thanks first to the strong underline megatrends and second to our proven ability to overtake the market in the segments. Turning to Life Science, we confirm our organic sales growth guidance and still view the core business as the main driver. Please note that we expect growth of the core business to normalize around Q4 and into next year.
Belén Garijo
executiveOur assumptions around COVID haven't changed. Specifically, for 2022 we anticipate COVID-related sales of up to €450 million in Process Solution, up to €250 million in Life Science Services, and roughly €100 million in Science and Lab Solutions. That gives a total of €800 million, which is the figure we communicated on our earlier calls. Also, as we said at the Capital Markets Day, we expect overall COVID sales to fall by at least 50% in 2023. On earnings, we've grown a bit more optimistic regarding organic EBITDA pre growth in Life Science for 2022, largely because of slightly lower OpEx. For healthcare, the story is quite straightforward. We fully confirm our organic growth guidance for both sales and EBITDA pre, with recent launches sustaining healthcare's main growth drivers. With that, thank you for your attention and your patience. We'll now be glad to take your questions.
Operator
operatorThanks. We're going to start the question-and-answer portion now. Our first question is from Richard Vosser at JPMorgan. Go ahead, your line is open.
Richard Vosser
analystHello, and thank you for taking my questions. I have two, please. First, regarding the Life Science or Process Solutions business: could you give us some sense of the underlying book-to-bill ratio? I realize that for the overall business it sits below one, but how does it look excluding COVID? Related to that, and bearing in mind what you mentioned about order intake normalizing somewhat as we move into 2023, along with the very substantial order book you still hold at a healthy level, how do you expect that to convert into growth across the coming 12 to 24 months? My second question concerns the semiconductor materials business within electronics, which again delivered very, very strong growth. I believe you have been signaling the idea that wafer volumes will decline as we go into 2023, so how should we think about that business over the next few quarters as we move ahead? Thank you very much.
Matthias Heinzel
executiveHi Richard, Matthias here. I’ll address your first question about PS and the book-to-bill. Sure, during the past several quarters, book-to-bill ratios across the whole PS business were very elevated, well above 1.3 , 1.4 . Clearly, that came from our long lead times. So with lead times now declining, we had anticipated and communicated earlier that the book-to-bill ratio would sit below one for a few quarters. That is what we already saw last quarter, when it was close to one, and now it is decreasing. We continue to see a very strong core business. We had 24% core. Last quarter, we have 31%. This quarter, we are very confident, given the business prospects, that we will keep seeing strong growth in the core, but it will normalize. So I’d give you one anchor point, certainly our midterm guidance, actually for total Life Science, and especially also for Process Solutions. So over the next few quarters, I’d suggest we will see a normalization toward that midterm guidance.
Kai Beckmann
executiveRichard, thanks for the question. This is Kai here. I'll address your semi question. Regarding the picture ahead of us, I'd like to give you some flavor on how the different areas within semi are composed. So first, as was presented, we have another turnkey project in DS&S, which gives us substantial additional opportunity to kind of avoid a cliff following the end of the current P3 project that we announced a year ago. So we now have a continuous trajectory of further turnkey opportunities. Second, the order book for our equipment business in DS&S is full. We're building new capacity. So no equipment indicator downturn affects us, since right now we can sell as much as we can produce. That's a good sign. Third, in the current environment we see predominantly the memory, the trailing edge memory nodes going down in capacitors, which is leading to the MSI decline you were referring to. That is the smallest area we service. So in trailing edge memory, that's a very small portion of our business. That's why we are less impacted by that. In the past quarter, since we integrated the zoom, that has led to an outperform of the MSI from above 800 basis points.
Kai Beckmann
executiveAnd that's pretty much the figure we've recorded on a quarter-over-quarter basis across the last two years. So that would mean the present forecast for next year sits down at minus 5% MSI development. We aren't as pessimistic as that figure might imply. I believe I've laid out for you all the reasons our composition ought to be rather strong.
Richard Vosser
analystThanks a lot.
Operator
operatorThanks. We’re going to skip to the next question, and it’s from Rosie Turner at Jefferies. Go ahead — your line is open.
Rosie Turner
analystHello, and thanks a lot for taking my questions. I have two, if that's all right. Sorry, but just to return to semis for a moment. I believe on slide 38 you made a remark about the DS&S project moving into the following year. So could we just get some clarity on whether that gives a reasonably good level of support for 2023, sort of irrespective of the remainder of the semis business? And then, just thinking about the deal we talked about at the Capital Markets Day, I think the intention is to carry out a transformational deal. Has any progress been achieved on that front? Or are the assumptions underlying it still unchanged as we move forward? Thank you very much.
Marcus Kuhnert
executiveRegarding Rosie's question, I'll address the semi question first, then DS&S and the shift occurring next year. The situation is fairly technical. What has moved is revenue recognition and the P&L, because we must factor in an accounting method tied to project progress. So invoicing has already been happening, yet it isn't recorded in the P&L — rather technical. Naturally, that was anticipated in the original projection for our landing in 2022, and it is now captured in 2023. Still, we're discussing only one quarter here. The remainder, as I noted in my earlier answer, is additional business in 2023. I'll hand it to Belen to flip over.
Belén Garijo
executiveHi Rosie, this is Belen, and thanks for your question. As you’re aware, at our Capital Markets Day we gave a fairly positive update on what we’re planning. Back then, we talked mostly about the financial capacity, which has now increased to roughly €15 billion to €20 billion, reflecting how well we’ve performed over the recent quarters and years. And that has opened the door for us to shift away from an exclusively bolt-on approach and in-licensing in pharma, for instance, toward eventually looking at larger moves if the opportunity arises. So our pipeline keeps expanding. We remain highly focused at the executive board level on making progress in these efforts, and what you should obviously expect is that we stay inside our strategic framework. And as we speed up, we may complement our organic outlook with inorganic moves centered on our Big 3 pillars.
Rosie Turner
analystThat’s all. Thank you so much.
Operator
operatorThanks. We'll move on to the next question now. Just a moment, please. It's from Sachin Jain at Bank of America. Go ahead, your line is open.
Sachin Jain
analystHi guys, Sachin Jain here from Bank of America. I have two sets of questions, please — one on electronics and one on process. So, a big-picture question on electronics: Belen and Kai, you've brought up macro uncertainty many times, and clearly electronics EBITDA went into decline for 2022. There are various scenarios for a decline, I guess, next year. But I wonder whether you could commit to group EBITDA growth for 2023 even if electronics is under macro-driven pressure, given the other divisions and productivity initiatives? And then secondly, on process — a two-part question. One, the underlying business accelerated sequentially from 24 to 31. What's driven that? And I guess what I'm trying to understand there is, if it's accelerating, why is it normalizing in the fourth quarter and then early into next year? And you talked about normalization to low mid teens? Just to be clear, that's, I think, ahead of where Danaher has guided for their normalization next year, a high single digit. So I'm just checking you're comfortable with that? Thank you.
Belén Garijo
executiveHi, Sachin. Thanks for those questions. On the first one, let me partly address it by saying, as we've said previously, that we expect our electronics business to run at a margin of roughly 30%. And at this point, maybe Kai can give a little more detail on deliveries.
Kai Beckmann
executiveSachin, one thing worth pointing out is that things on the semi margin front are pretty steady, even with all those effects we talked about earlier. Marcus's slides showed this. The pressure we've felt this year — the thing that drove the change to our guidance — comes from the outright contribution of Display Solutions, which is under pressure at the moment. Based on the current data, which is softening, we hope that situation improves over the course of next year; that's at least what the market data's durability suggests. So that piece is easing, while obviously the inflationary environment remains. Still, margins in semi solutions are pretty steady. That certainly gives us confidence going into next year.
Matthias Heinzel
executiveYes. Hello, Sachin, this is Matthias. Regarding your question about PS. Indeed, we did experience a short-term pickup in our PS business — 24% in the prior quarter and 31% in this one. That really stems from two factors, correct. We've added new capacity and are ramping it up, and simultaneously, as COVID is sort of fading, we can now devote that plus extra capacity more toward core business growth. And we keep expecting to see that over the coming couple of quarters. Still, it will normalize across the next several quarters. Again, as I said in the midterm — in the midterm guidance, nothing was included for 2023 yet. But expect very strong growth for PS, core growth, in 2023 and beyond. Yet at the same time, we have to recognize that the COVID deceleration and, as Belen mentioned, the more than 50% decline next year. That is kind of being layered on top of that core growth.
Sachin Jain
analystThanks.
Operator
operatorThanks. We won’t move on to the next question. It’s from Peter Verdult at Citi. Go ahead. Your line is open.
Peter Verdult
analystThanks. This is Peter Verdult from Citi, with a couple of questions. Apologies to both Peter and Marcus, but it's semiconductors and Life Science once more. First, Matthias, could you put a rough number on the advantage you saw in Q3 from customers buying forward before the price rises you implemented in October? And at a high level on Life Science pricing trends, could you give some approximate figures for the percentage gains you achieved in 2022 across the entire portfolio and, if you're comfortable, for Process Solutions specifically? Also, anything you can share on how you view the pricing outlook ahead? The reason I ask is that I believe you mentioned 7% pricing for next year, and I wanted to check that with you for consistency. Then Kai, sorry to return to electronics, but just so I'm clear: during the first few months of Q4, we have seen no softening in trends and semis. And it is absolutely 100% a displacing dynamic that drove the change in guidance — I want to confirm I've got that right? Thank you.
Matthias Heinzel
executiveHey, Peter, I'll take that first question. So pricing is a major lever for us to offset inflation, and we've built up solid pricing momentum. I think I've said this before — I feel we have strong pricing capabilities. And roughly for the full year, it remains in the range I indicated earlier: we're at about 2.5x historic levels, right, which historically was about 1.2. And keep in mind, we're talking about the net price effect. Obviously, the list price increases are higher, but what counts is what really sticks in the end. And that's around two point x across the board, and obviously we'll do that in all three of our businesses — PS, SLS and Life Science Services. On your question about the forward effect in SLS: it's small. It does have an impact. But it's a small pull-forward. Because typically when you raise price, there's some anticipation from customers and they place an order earlier. But it's not a major effect in our numbers.
Kai Beckmann
executiveLet me address the semi question. The revision to our guidance came mainly at the top line — the DS&S pacing to tweet, as I walked through in detail earlier — and on EBITDA, to close the display situation the way you described. Broadly speaking, those were the two factors that shifted things for how the year ends.
Peter Verdult
analystI appreciate that.
Operator
operatorThanks. We won’t take the next question. It’s from the line of Wimal Kapadia at Bernstein. Please go ahead. Your line is open.
Wimal Kapadia
analystThanks so much for taking my questions. First, going back to something UK mentioned earlier about state semis being stable on the margin side — historically that has pointed to decent pricing power in semis over recent quarters. I'm wondering whether that actually shifts in a setting where MSCI is declining. It sounds like you still hold that pricing power, but does it get affected when the market is deteriorating? Then maybe one last question on Pharma. A few of the older brands look especially strong, and you point to emerging markets as a key growth driver. I guess is there any specific one-off you'd call out there? Is it just solid underlying performance, and should we really expect that kind of momentum to carry on in the coming quarters? Thanks very much.
Marcus Kuhnert
executiveLet me address the semi question first. Growth is driven by three things, and pricing isn't the only one. There's a mix effect, since our strongest business in films is growing faster and that adds positively to mix. Second, we have very robust volume growth underneath. And then pricing sits on top of that in selected areas where we account for inflation. But it's that combination. So I'd call this a fairly resilient picture. It isn't one that hinges on a single event, as you may have implied.
Matthias Heinzel
executiveYes. Wimal, regarding your question about Pharma. So I believe Marcus has clearly identified the one-time effects related to Refib channel management. Beyond that, there really isn't anything else that qualifies as one-off, correct? So what you're seeing is that performance is strong across the board. We have contributions from the launches. We have a very healthy 6% growth in the CM&E business. We have fertility recovering after the lockdown impact in Q2. And we are once again trending upward toward our mid single digit guidance for the midterm. Still with the caveat of possible volatility depending on essentially what happens in China with additional lockdowns, you have also seen very healthy performance for Erbitux. We mentioned to you at the Capital Markets Day that this product is increasingly being used as a backbone for other therapies. We have plenty of studies ongoing, either by ourselves or by other colleagues. So, I would say it's a pretty decent performance, essentially across geographies and across franchises.
Wimal Kapadia
analystThanks.
Operator
operatorThanks. We won’t take the next question. It’s from Gary Steventon at BNP Paribas Exane. Go ahead—your line is open.
Gary Steventon
analystThank you. I'd like to start by returning to the electronics margin topic, since you mentioned guidance of roughly 30%, and we saw margins reach the 32% mark back in 2019. Given that display is under pressure now, it seems fairly reasonable that the meaning of "around" could stretch about 200 basis points downward as well. So I just wanted to ask how confident you are that electronics margins can stay inside those guard rails—say, plus or minus 200 basis points—around that 30% mark in the near term. And are there any levers you could describe that are available to you for shielding the divisional margin from slipping further? Then, if I may, I'd also like to ask about Life Science services. You noted near-term volatility from the unfavorable batch phasing, which I assume is simply part of the business, but also attrition in the clinical pipeline. On phasing, is there anything you can flag for us regarding Q4, since we're now almost halfway through that quarter? And on pipeline attrition, one of the largest CDMOs commented that they're seeing customers prioritize developing earlier-stage assets and described it as a cash conscious decision.
Gary Steventon
analystAnd we're seeing that with both large pharma and biotech customers. So I just wanted to check whether you're noticing any effect there as well. Or is the attrition simply being amplified because the business is smaller and there's customer concentration? Thank you.
Belén Garijo
executiveGary, I'll just restate what I've already told you in response to essentially that same question. So, as I mentioned earlier, we have reasonable confidence that we can deliver on electronic margins of around 30%, as we've previously stated, even with the pressures we've been experiencing in display. That's because we believe the display impact we're currently absorbing is going to reverse at some point in the quarters ahead.
Matthias Heinzel
executiveHi, Gary. This is Matthias. Let me take your question about LSS. Maybe some context helps. LSS is made up of two businesses. The first is our testing business, which is well established. We have several hundred customers. Its growth is very robust and resilient. Then there's our CDMO business, which is the other half — actually a bit more than that — where we're really starting from a much smaller scale to grow that business. We're very confident. But as we said earlier, because of the smaller scale and the smaller customer count, things fluctuate a bit more, if you will. And as we mentioned, and you echoed as well, we depend somewhat more on individual customer programs and how those programs turn out. That's essentially what explains the volatility, which we'll also see over the next couple of quarters, but that doesn't jeopardize our long-term belief in and commitment to the business. That's basically the CDMO. That's not to address that element of your question. Biotech funding has some impact, but we're not seeing a major impact. By and large, we have large pharma customers in our CDMO business, and smaller biotechs.
Matthias Heinzel
executiveSure, they might focus a bit more on spreading the cost out, but that isn't a major impact on LSS growth.
Gary Steventon
analystAll right, thanks so much.
Operator
operatorThanks. Now we'll move on to the next question, which is from James Quigley at Morgan Stanley. Your line is open — please go ahead.
James Quigley
analystAlright, thank you for the opportunity to ask. I have one question about Life Sciences and another about Pharma, with the Pharma one as a follow-up. In Science and Lab Solutions, we saw yet another quarter of very strong growth. That said, how do you view the core growth outlook over the short to medium term, given possible headwinds such as biotech funding? What is happening with biotech funding recovery, and what about possible recessionary effects on areas like academic funding — NIH funding appears to be trending negatively, and that has historically mattered a lot for the research solutions business — and then also any possible impact on the applied segments from the global downturn. Then on pharma, as a follow-up to Wimal's question about the January portfolio, CM&E in particular was quite solid this quarter. So looking ahead, is there any reason those growth rates should begin to slow? I know there was a fairly easy comp for certain products within the CM&E franchise. But are there any other effects that might potentially lead despite the growth slowing down? And then just one very quick one on Mavenclad as well. Could you update us on how Mavenclad is performing geographically, so the split of U.S.
James Quigley
analystAnd would that safeguard U.S. sales? Then, if you have any remarks on market share across the various regions, given the awkwardness and the symptom of growing faster? Thank you.
Matthias Heinzel
executiveHi James, Matthias here. I'll begin with what you asked about SLS. We're genuinely doing well in SLS this year, I'd say. Q3 showed really solid growth at 7.9%. And it's definitely worth pointing out how strong our pricing momentum is here too. I believe I touched on that earlier, but it holds true, particularly in our SLS business as well. There's also some effect in China right after the lockdown, similar to what we saw in previous quarters — we're seeing nice growth there, things are picking up. So yes, we feel very confident about SLS. That said, I'd expect us to gradually move toward our midterm guidance over time, which we gave as the low to mid teens. Now, on your recession question. I see this as a very resilient business, correct? We're spread widely across regions. Our customer base is quite large and spans different sectors, right? There's academia, pharma. Academia, pharma, industrial. So once more, I want to restate what I said. It's low to mid single digit, the midterm guidance. So I think I misspoke earlier. It's low to mid single digit, and we're very confident we'll get there.
Matthias Heinzel
executiveIs that clear?
Marcus Kuhnert
executiveThank you, James, for that question. Regarding CM&E, the plus 6% you observed this quarter is actually near the guidance we provided for the midterm, which sits at mid single digits. So naturally, we're quite pleased with this quarter. That said, nothing suggests this momentum will lose steam going forward. It's a fairly diversified franchise within healthcare, with plenty of ups and downs, but as the slides showed, products such as Euthyrox are up 12 and in double digits, while Concor is growing 4%. So it really is a portfolio that's growing quite nicely. Let me remind you that particularly across emerging markets, the count of patients receiving treatment for some of these conditions stays extremely low. So essentially, a volume opportunity persists, and naturally we're working to capture it. Even though fertility wasn't part of your question, keep in mind that among established products, we also have a dynamic fertility business, again with mid single digit guidance that we shared with you. And then lastly, on Mavenclad, the trends we've observed over the past few quarters really haven't shifted fundamentally by country. So what we see is a relatively stable U.S.
Marcus Kuhnert
executiveSo it's a smaller opportunity for us in the first line, but we do pick up share in the oral marketplace — mostly, though not only, in the second line in the U.S. and outside the U.S., where the label genuinely lets us compete on equal footing. In first line, we truly perform well. I think we keep gaining share. In fact, we're leading the market, and in certain European countries, Spain for instance. And so we do see brands outside the U.S. that are significantly more dynamic than ours. But overall, as you've seen, the brand is still growing.
James Quigley
analystAppreciate it.
Operator
operatorThanks. We’re going to skip ahead to the next question. It’s from Michael Leuchten at UBS. Go right ahead. Your line is open.
Michael Leuchten
analystThanks a lot. It’s Michael Leuchten from UBS. Coming back to what Matthias said, I believe the book-to-bill ratio is being somewhat misread, since it contains two elements. The first is lead time, and clearly there is at least some risk that inventory sits in the channels. I was just wondering whether you could address the visibility you actually have on that. At the CMD, you did state that you aren’t concerned. Still, I wanted to ask: given how uncertain conditions are, is there really visibility, and how can you measure it? Thank you.
Matthias Heinzel
executiveSure. Thanks. Now, a book-to-bill ratio under one is something we anticipated, correct? I'd like to repeat my earlier point: because of the extremely large order book — a very substantial backlog we've built up over time — with lead times shrinking, that ratio is going to drop under one across the coming several quarters. Our visibility is genuinely solid. It varies somewhat depending on the business, obviously, but in PS we have quite strong visibility, since lead times remain at three, six months. So once more, that gives us confidence. And again, I want to convey confidence that even a book-to-bill under one for a few quarters does not put at risk our commitment to, and confidence in, the business's long-term growth.
Operator
operatorThanks. We’re moving on to the next question now. Please hold on. The next question is from Florent Cespedes at — sorry, Florent with Societe Generale. My apologies, sir.
Constantin Fest
executiveFlorent, you have the floor. Your line is open.
Operator
operatorFlorent, you’re up.
Florent Cespedes
analystIs my voice coming through?
Operator
operatorIt's a little improved at this point. Yes, sir.
Belén Garijo
executiveYes, we hear you.
Florent Cespedes
analystAll right, and sorry about that. Thanks so much. I have two quick questions. First, regarding Display Solutions: would you mind adding some detail on the reasons you expect somewhat less deterioration ahead? Is any new capacity coming onstream? Might there be additional pricing pressure down the road? Some color there would be very helpful. My second question concerns . Could you expand a bit on how things stand in China across your various products, and also address specifically the facility in China as well as those in other countries? Thanks a lot.
Marcus Kuhnert
executiveFlorent, I'll address the display question first. And regarding display, what we're seeing at present is that within the market where we participate, we have not lost any market share. It's purely a matter of utilization, maybe on the part of our customers. They've dropped to a level that we have not seen previously. Right now, even certain lines are entirely shut down, owing to reduced consumer demand. That won't continue indefinitely. They will come back to a normal utilization of the, perhaps over the course of next year. Date to be seen. But it gives — so, since we have not lost market share, that gives us confidence regarding the way forward that once they ramp up again, we participate in these ramp ups again as far as our business is concerned.
Matthias Heinzel
executiveYes, Florent — thanks for raising that. Apologies. Appreciate the question, Florent, regarding China. I believe everyone needs to recognize that the lockdown situation hasn't ended. Some of the smaller provinces are still under lockdowns. And as we're aware, our fertility business tends to be somewhat more exposed to those lockdowns overall. That said, fertility looked more dynamic in Q3 than it did in Q2. Still, the situation obviously stays fairly fluid. On the flip side, with Erbitux, our exposure to lockdowns is much lower, if there's any exposure at all. And in fact, as I said, I believe on the last call, momentum for Erbitux in China is very, very positive. At this point we have not only the CRC indication but also the head and neck indication on the NRDL since the start of this year, so that's certainly a plus. And finally, I'd also point to some of the CM&E brands. The Euthyrox business is quite dynamic, our concor business is quite dynamic, and Glucophage as well, which has now passed, I'd say, the trough of the PDP process wave. So many moving parts, but on the whole a satisfactory performance.
Florent Cespedes
analystThanks a lot.
Operator
operatorAppreciate it. We're ready for the following question, which is coming from Falko Friedrichs at Deutsche Bank. The line is yours — please proceed.
Falko Friedrichs
analystThanks a lot. My first question is about the display business coming back, and it follows up on what was asked before. Is it realistic to think that recovery in that business might occur during the first half of next year? Or would it be more reasonable to expect it in the second half instead? Then for my second question, could you say a little about how Bavencio performed in Q3? And was all of that consistent with what you had expected? Thank you.
Belén Garijo
executivePeter, go ahead and start with Bavencio.
Peter Guenter
executiveYes. Well, regarding Bavencio — I appreciate the question. What you’re seeing is that each quarter brings solid growth, whether measured against the corresponding period a year earlier or on a sequential basis. Really, this comes down to two factors. First, in markets where we’ve already launched, we keep observing momentum gathering around chemotherapy use and patients being eligible for platin. The maintenance regimen is being adopted as the new standard of care. And then, naturally, there’s the use of Bavencio within that scheme. So that has continued to progress nicely. Then there’s a second factor, which is, naturally, the addition of what we might term late-launch countries. As one example, we only obtained pricing and reimbursement in Spain, I believe roughly five or six months ago, and the same in Italy. So this is typically the effect you observe in those later pricing and reimbursement markets. So again, a pretty homogeneous performance for Bavencio — U.S., Europe, Japan, other countries. So we’re quite, quite pleased with that. And also, at the latest ESMO conference, we were very excited to communicate that in a subgroup of patients who had received the product for more than 12 months now, mean overall survival had still not been reached.
Peter Guenter
executiveAnd the average progression-free survival came in at 26.7 months, with no new safety signals showing up. So in this group of long-term responders, we truly see strong and rapid clinical benefit.
Kai Beckmann
executiveOkay, Falko, I’ll handle the display question. From where we stand today, can we predict whether this will land in the first half or the second half? Just as a reminder, this represents 20% of electronics and 4% of the coop, so I’d say we aren’t especially anxious about precisely when it comes back.
Falko Friedrichs
analystAlright, thanks.
Operator
operatorThanks. We're not going to take the next question. It's from Oliver Metzger at ODDO BHF. Please go ahead. Your line is open.
Analyst
analystGood afternoon, and thank you for taking my questions. My first question is also about display solutions. You discussed the anticipated recoveries at length, and the timing of some of them. However, when I consider the underlying momentum of the business over a multi-year horizon, where is the clear downward trend at present, and could there potentially be an acceleration to the downside that is too strong? What does that imply for your business in terms of scale? Are there any steps being taken to rescale the business while it remains negative for a period? My second question concerns revenues tied to COVID. Your guidance still stands at €700 million. When compared with concerns about infection rates resurging, or incidence levels, these days, along with slowing booster vaccination rates, it appears corona-related revenues have less support than was the case a couple of months ago. By my calculations, you had a €1.6 million COVID tailwind. So I would ask why you are sticking with this $700 million, since earlier this year you mentioned the €170 million quarterly run rate, and my calculation comes out at a lower amount?
Belén Garijo
executiveOkay, Oliver — thanks, Oliver. Let me restate what Kai Beckman just mentioned. Let's frame the display conversation properly, because ultimately our electronics business today consists of semiconductors, it's powered by semiconductors, and the future of electronics lies with semiconductors, which already account for 70% of revenues at present and are expanding, as you saw in the Q3 report, growing at a double-digit rate, solidly ahead of markets, and very well positioned to compete. Now, display solutions would account for 3% to 3.5% of the total group, correct? And if you factor that in, the question of when customer behavior returns to a more normal pattern doesn't matter much. I mean, we can't forecast when we'll get there or how quickly this ramps up. But what we're saying is that it won't change our midterm perspectives or the commitments we've already made to the market. And on COVID, I'll hand it to Matthias.
Matthias Heinzel
executiveYes. Thank you, Belen. Let me take the COVID question. We are indeed reconfirming. Our figures for processor uses reach up to 450 million, and after 250, plus roughly 100 SLS, which gives you about 800 for this year. Naturally, we have fairly solid visibility on that. That said, we clearly are seeing a significant drop. And we provided an indication of a decline greater than 50% for next year. Of course, that is founded on the order intake, which came earlier, as I mentioned. But yes, for this year certainly, we confirm our figure of 800 million with the mix I just described.
Analyst
analystAll right, thanks.
Belén Garijo
executiveI appreciate that.
Operator
operatorThanks. We’ll move on to the next question now. Today’s final question is from Simon Baker at Redburn. Go ahead — your line is open.
Simon Baker
analystThanks for taking my questions, and I hope it's okay if I ask a couple. First, on Life Science: we've discussed lower lead times quite a bit, but unless I missed it, you haven't told us how much those lead times have actually changed. Could you share anything about the shift in lead time? I ask because, regarding the book-to-bill ratio, we've been concentrating on the numerator's impact. Still, I was wondering whether rising capacity and shorter lead times have also been helping push book-to-bill down for now. Second, on semiconductors: there have been various suggestions and reports in the market about a slowdown in the ramp of the three nanometer rollout. I'd be interested to know what you've been hearing, plus your exposure and how important the three nanometer ramp-up is to near-term growth. Thanks so much.
Matthias Heinzel
executiveThanks, Simon — this is Matthias. I'll take your question about lead times. And you're right that in quite a few parts of the portfolio, lead times have fallen by over 50%. I'd rather not get into specific product lines, but take NovaSeptum — our sampling packs — which went from 26 weeks down to 13 weeks, just to give you a sense. So I think we're making solid progress, and we're also making solid progress getting the new capacity up and running. That combination, of course, affects book-to-bill, as I explained. But we definitely need the next several quarters, across the whole PS portfolio, to get lead times back to the level we had before. Again, good progress is being made. In many areas we've come down by more than 50%. But we're not yet at the pre-COVID level.
Marcus Kuhnert
executiveSimon, regarding their three-nanometer delay — it's fairly typical for new nodes, or the newest technologies, to slip, and the nearer the expected launch date gets, the more that tends to happen. So there's nothing unusual here. And maybe on top of that, in downturns, what past semiconductor downturns have shown us is that node transitions speed up. Because our customers have extra tool time, since they're running at lower utilization. They use that tool time to get new technologies going. So all those players mainly concentrated on high-end technologies — which is our portfolio — hold an advantage in this downturn, because node transitions accelerate. So I'm more on that side of things, optimistic; the three-nanometer technology itself doesn't really matter on the larger scale.
Simon Baker
analystMuch appreciated.
Marcus Kuhnert
executiveThose were every one of the questions we had. And with that, I'd like to pass things over to Belen for some closing remarks.
Belén Garijo
executiveTo start, I really appreciate everyone joining our earnings call. If you factor in the macro backdrop and what input costs are doing to our business, then I'd say what we achieved in Q3 qualifies as very strong growth — resilient growth. Once again, this really reflects how our diversified business model gives us resilience. So while we keep posting solid quarterly results in the short term, we're also continuing to drive, implement, and execute against our strategic agenda. That's why we think the external headwinds are unlikely to assume. We have fully confirmed our guidance for this year and stay firmly committed to our midterm growth ambition. With that, I look forward to meeting many of you at the upcoming meetings and conferences. And goodbye for now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Merck KGaA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Merck KGaA earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck KGaA or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.